Capital Research Global Investors’s Ionis Pharmaceuticals IONS Stock Holding History

Capital Research Global Investors’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$24.3M	Buy	+323,015	New	+$25.5M	﹤0.01%	402

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors's IONS Position: Q1 2026 in Review

Capital Research Global Investors opened a new position in Ionis Pharmaceuticals (IONS) in Q1 2026: 323,015 shares worth $24.3M. The stake represents ﹤0.01% of the portfolio and ranks #402 among its holdings.

494 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

Capital Research Global Investors held 323,015 shares of Ionis Pharmaceuticals worth $24.3M as of Q1 2026.
Ionis Pharmaceuticals was a new Capital Research Global Investors position in Q1 2026.
Ionis Pharmaceuticals made up ﹤0.01% of Capital Research Global Investors's portfolio in Q1 2026, its #402 holding.
494 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Capital Research Global Investors's 13F filing for Q1 2026, filed 13 May 2026.